Supplementary Figure 1 from Depleting the Action of EZH2 through PI3K–mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer

This is a Experimental Study study.

Key Points

PI3K-mTOR blockade significantly inhibits cell proliferation in triple-negative breast cancer (TNBC) cells.
Next-generation therapies targeting EZH2 and PI3K-mTOR pathways may enhance treatment efficacy in TNBC.
This analysis examines the role of ATM inhibition in combatting cancer cell survival with immunotherapy resistance.
Future research should further explore personalized treatment strategies involving PI3K-mTOR and EZH2 inhibition in TNBC patients.

We only have this paper's title and publication details.

Analysis shows PI3K-mTOR inhibition reduces proliferation in TNBC cells, suggesting a new treatment avenue.

Supplementary Figure 1. PI3K-mTOR blockade inhibits proliferation of TNBC cells

No takes yet. Share an insight, caveat, or question.

Melino et al. (2025) studied this question.

View at Publisher

Ask AI

Bookmark

Share